$BCDA
BioCardia, Inc. Stock $bcda

$bcda Overview Financials Valuation SEC Filings Company Website

2017 Form 10-K Financial Statement

#000143774918004870 Filed on March 16, 2018

Income Statement

Concept	2017	2016 Q4	2016
Revenue	$479.0K	-$5.220M	$576.0K
YoY Change	-16.84%	-3828.57%	-36.28%
Cost Of Revenue	$690.0K		$746.0K
YoY Change	-7.51%		-29.69%
Gross Profit	-$211.0K		-$170.0K
YoY Change	24.12%		8.28%
Gross Profit Margin	-44.05%		-29.51%
Selling, General & Admin	$6.395M	$3.590M	$4.108M
YoY Change	55.67%	7080.0%	10.02%
% of Gross Profit
Research & Development	$5.799M		$3.330M
YoY Change	74.14%		119.37%
% of Gross Profit
Depreciation & Amortization	$78.00K		$39.00K
YoY Change	100.0%		-17.02%
% of Gross Profit
Operating Expenses	$12.19M	$7.670M	$7.438M
YoY Change	63.94%	15240.0%	41.62%
Operating Profit	-$12.41M		-$7.608M
YoY Change	63.05%		40.65%
Interest Expense		-$2.960M	$1.736M
YoY Change			25.25%
% of Operating Profit
Other Income/Expense, Net	$97.00K		-$2.702M
YoY Change	-103.59%		109.78%
Pretax Income	-$12.31M	-$15.59M	-$10.31M
YoY Change	19.4%	-17422.22%	53.88%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$12.31M	-$15.59M	-$10.31M
YoY Change	19.38%	-17422.22%	53.95%
Net Earnings / Revenue	-2569.52%		-1789.93%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.903M	-$13.56M	-$11.09M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2017	2016 Q4	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.69M	$21.35M	$21.35M
YoY Change	-40.56%	54.26%	54.26%
Cash & Equivalents	$12.69M	$21.35M	$21.35M
Short-Term Investments
Other Short-Term Assets	$340.0K	$360.0K	$360.0K
YoY Change	-5.56%	800.0%	800.0%
Inventory	$190.0K	$135.0K	$140.0K
Prepaid Expenses		$356.0K
Receivables	$100.0K	$74.00K	$70.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.32M	$21.92M	$21.92M
YoY Change	-39.23%	369.42%	57.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$170.0K	$111.0K	$110.0K
YoY Change	54.55%	-26.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00K	$54.00K	$50.00K
YoY Change	0.0%	25.58%
Total Long-Term Assets	$220.0K	$165.0K	$160.0K
YoY Change	37.5%	-14.51%
TOTAL ASSETS
Total Short-Term Assets	$13.32M	$21.92M	$21.92M
Total Long-Term Assets	$220.0K	$165.0K	$160.0K
Total Assets	$13.54M	$22.08M	$22.08M
YoY Change	-38.68%	354.18%	59.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$900.0K	$525.0K	$530.0K
YoY Change	69.81%	-3.14%	5200.0%
Accrued Expenses	$540.0K	$478.0K	$540.0K
YoY Change	0.0%	-30.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.330M	$1.444M	$1.440M
YoY Change	61.81%	-82.61%	14300.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$80.00K	$60.00K	$60.00K
YoY Change	33.33%
Total Long-Term Liabilities	$80.00K	$60.00K	$60.00K
YoY Change	33.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.330M	$1.444M	$1.440M
Total Long-Term Liabilities	$80.00K	$60.00K	$60.00K
Total Liabilities	$2.410M	$1.500M	$1.500M
YoY Change	60.67%	-81.94%	14900.0%
SHAREHOLDERS EQUITY
Retained Earnings		-$60.14M
YoY Change		20.69%
Common Stock		$38.00K
YoY Change		100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.13M	$20.58M	$20.58M
YoY Change
Total Liabilities & Shareholders Equity	$13.54M	$22.08M	$22.08M
YoY Change	-38.68%	354.18%	59.08%

Cashflow Statement

Concept	2017	2016 Q4	2016
OPERATING ACTIVITIES
Net Income	-$12.31M	-$15.59M	-$10.31M
YoY Change	19.38%	-17422.22%	53.95%
Depreciation, Depletion And Amortization	$78.00K		$39.00K
YoY Change	100.0%		-17.02%
Cash From Operating Activities	-$8.671M	-$2.510M	-$5.522M
YoY Change	57.03%	-2381.82%	-21.37%
INVESTING ACTIVITIES
Capital Expenditures	$136.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$18.92M	$18.92M
YoY Change	-100.0%
Cash From Investing Activities	-$136.0K	$18.92M	$18.92M
YoY Change	-100.72%		-15236.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	144.0K	4.400M	4.396M
YoY Change	-96.72%		-41.55%
NET CHANGE
Cash From Operating Activities	-8.671M	-2.510M	-5.522M
Cash From Investing Activities	-136.0K	18.92M	18.92M
Cash From Financing Activities	144.0K	4.400M	4.396M
Net Change In Cash	-8.663M	20.81M	17.80M
YoY Change	-148.68%	18818.18%	4670.78%
FREE CASH FLOW
Cash From Operating Activities	-$8.671M	-$2.510M	-$5.522M
Capital Expenditures	$136.0K	$0.00
Free Cash Flow	-$8.807M	-$2.510M	-$5.522M
YoY Change	59.49%		-22.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017Q4	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	1263000
CY2016Q4	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	848000
CY2016	bcda	Adjustments To Additional Paid In Capital Reclassification Of Convertible Shareholder Notes Derivative Liability AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertibleShareholderNotesDerivativeLiability	2268000
CY2017	bcda	Cash Acquired In Reverse Merger CashAcquiredInReverseMerger
CY2016	bcda	Cash Acquired In Reverse Merger CashAcquiredInReverseMerger	19017000
CY2015	bcda	Cash Acquired In Reverse Merger CashAcquiredInReverseMerger
CY2017	bcda	Change In Fair Value Of Convertible Preferred Stock Warrant Liability ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
CY2016	bcda	Change In Fair Value Of Convertible Preferred Stock Warrant Liability ChangeInFairValueOfConvertiblePreferredStockWarrantLiability	250000
CY2015	bcda	Change In Fair Value Of Convertible Preferred Stock Warrant Liability ChangeInFairValueOfConvertiblePreferredStockWarrantLiability	274000
CY2017	bcda	Change In Fair Value Of Convertible Shareholder Notes Derivative Liability ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability
CY2016	bcda	Change In Fair Value Of Convertible Shareholder Notes Derivative Liability ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability	-1224000
CY2015	bcda	Change In Fair Value Of Convertible Shareholder Notes Derivative Liability ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability	1373000
CY2017	bcda	Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability
CY2016	bcda	Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability	10000
CY2015	bcda	Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability	87000
CY2017	bcda	Changes In Deferred Tax Assets Before Valuation Allowance Due To Changes In Enacted Tax Rate ChangesInDeferredTaxAssetsBeforeValuationAllowanceDueToChangesInEnactedTaxRate	-8200000
CY2017	bcda	Collaboration Agreement Revenue CollaborationAgreementRevenue	90000
CY2016	bcda	Collaboration Agreement Revenue CollaborationAgreementRevenue	59000
CY2015	bcda	Collaboration Agreement Revenue CollaborationAgreementRevenue	44000
CY2017Q4	bcda	Deferred Tax Assets Net Operating Loss And Tax Credit Carryforwards Noncurrent DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwardsNoncurrent	17368000
CY2016Q4	bcda	Deferred Tax Assets Net Operating Loss And Tax Credit Carryforwards Noncurrent DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwardsNoncurrent	20196000
CY2017	bcda	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestAmount
CY2016	bcda	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestAmount	590000
CY2015	bcda	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestAmount	471000
CY2017	bcda	Effective Income Tax Rate Reconciliation Warrant And Derivative Revaluation Amount EffectiveIncomeTaxRateReconciliationWarrantAndDerivativeRevaluationAmount
CY2016	bcda	Effective Income Tax Rate Reconciliation Warrant And Derivative Revaluation Amount EffectiveIncomeTaxRateReconciliationWarrantAndDerivativeRevaluationAmount	328000
CY2015	bcda	Effective Income Tax Rate Reconciliation Warrant And Derivative Revaluation Amount EffectiveIncomeTaxRateReconciliationWarrantAndDerivativeRevaluationAmount	-589000
CY2017	bcda	Exchange Of Convertible Preferred Stock Warrants For Common Stock ExchangeOfConvertiblePreferredStockWarrantsForCommonStock
CY2016	bcda	Exchange Of Convertible Preferred Stock Warrants For Common Stock ExchangeOfConvertiblePreferredStockWarrantsForCommonStock	25000
CY2015	bcda	Exchange Of Convertible Preferred Stock Warrants For Common Stock ExchangeOfConvertiblePreferredStockWarrantsForCommonStock
CY2017Q4	bcda	Grant Liability Current GrantLiabilityCurrent	663000
CY2016Q4	bcda	Grant Liability Current GrantLiabilityCurrent	304000
CY2017Q3	bcda	Holders Of Issued And Outstanding Shares Of Voting Stock Agreed With Reverse Stock Split Percent HoldersOfIssuedAndOutstandingSharesOfVotingStockAgreedWithReverseStockSplitPercent	0.636
CY2017	bcda	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts
CY2016	bcda	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts
CY2015	bcda	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts	-48000
CY2017	bcda	Payments Of Transaction Costs For Reverse Merger PaymentsOfTransactionCostsForReverseMerger
CY2016	bcda	Payments Of Transaction Costs For Reverse Merger PaymentsOfTransactionCostsForReverseMerger	96000
CY2015	bcda	Payments Of Transaction Costs For Reverse Merger PaymentsOfTransactionCostsForReverseMerger
CY2015	bcda	Permanent Equity Reclassified From Temporary Equity PermanentEquityReclassifiedFromTemporaryEquity	38213000
CY2017	bcda	Proceeds From Issuance Of Convertible Notes And Warrants ProceedsFromIssuanceOfConvertibleNotesAndWarrants
CY2016	bcda	Proceeds From Issuance Of Convertible Notes And Warrants ProceedsFromIssuanceOfConvertibleNotesAndWarrants	4374000
CY2015	bcda	Proceeds From Issuance Of Convertible Notes And Warrants ProceedsFromIssuanceOfConvertibleNotesAndWarrants	7435000
CY2017	bcda	Reclassification Of Convertible Shareholder Notes Derivative Liability ReclassificationOfConvertibleShareholderNotesDerivativeLiability
CY2016	bcda	Reclassification Of Convertible Shareholder Notes Derivative Liability ReclassificationOfConvertibleShareholderNotesDerivativeLiability	2268000
CY2015	bcda	Reclassification Of Convertible Shareholder Notes Derivative Liability ReclassificationOfConvertibleShareholderNotesDerivativeLiability
CY2016Q4	bcda	Sales Returns Reserve SalesReturnsReserve	1000
CY2017Q4	bcda	Sales Returns Reserve SalesReturnsReserve	1000
CY2017Q4	bcda	Share Based Compensation Arrangement By Share Based Payment Award Options Unexercisable Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnexercisableIntrinsicValue	1046000
CY2017	bcda	Share Based Compensation Arrangement By Share Based Payment Award Options Unexercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnexercisableWeightedAverageRemainingContractualTerm	P8Y292D
CY2017Q4	bcda	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unexercisable Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnexercisableNumber	2656866
CY2016Q4	us-gaap	Assets Assets	22082000
CY2017Q4	bcda	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unexercisable Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnexercisableWeightedAverageExercisePrice	3.36
CY2017	bcda	Standard Product Warranty Term StandardProductWarrantyTerm	P2Y
CY2016Q4	bcda	Stock Issued During Period Value Exchange Of Convertible Preferred Stock Warrants To Common Stock StockIssuedDuringPeriodValueExchangeOfConvertiblePreferredStockWarrantsToCommonStock	25000
CY2016	bcda	Stock Issued During Period Value Exchange Of Convertible Preferred Stock Warrants To Common Stock StockIssuedDuringPeriodValueExchangeOfConvertiblePreferredStockWarrantsToCommonStock	25000
CY2015	bcda	Stock Issued During Period Value Exercise Of Convertible Preferred Stock Warrants For Series D Preferred Shares StockIssuedDuringPeriodValueExerciseOfConvertiblePreferredStockWarrantsForSeriesDPreferredShares	34000
CY2015	bcda	Stock Issued During Period Value Exercise Of Convertible Preferred Stock Warrants For Series F Preferred Shares StockIssuedDuringPeriodValueExerciseOfConvertiblePreferredStockWarrantsForSeriesFPreferredShares	2000
CY2016	bcda	Stock Issued During Period Value Recapitalization For Reverse Merger StockIssuedDuringPeriodValueRecapitalizationForReverseMerger	18921000
CY2015	bcda	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts	1634000
CY2017	bcda	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts
CY2016	bcda	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	902000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	525000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	95000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	74000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	539000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	478000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	758000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	771000
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83537000
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80686000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	283000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	942000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2707000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2707000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	942000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	283000
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4311096
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3491937
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19283456
CY2017Q4	us-gaap	Assets Assets	13538000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	13315000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	21917000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12689000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21352000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3557000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3184000
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8663000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	17795000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	373000
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1061000
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	12884000
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	8184000
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	6313000
CY2017Q4	us-gaap	Customer Deposits Current CustomerDepositsCurrent	61000
CY2016Q4	us-gaap	Customer Deposits Current CustomerDepositsCurrent	66000
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	12156000
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7781000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	71000
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38218660
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38131303
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38218660
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38131303
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	38000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	38000
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 36pt;"></td> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(e)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentration of Credit Risk</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: 0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>the Company’s cash was held by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> financial institution and the amount on deposit was in excess of FDIC insurance limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recognized any losses from credit risks on such accounts since inception. The Company believes it is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> exposed to significant credit risk on cash.</div></div></div></div>
CY2017	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1
CY2016	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	46030000
CY2015	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	690000
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	746000
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	81000
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	56000
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	167000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18665000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21630000
CY2017Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	449000
CY2016Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	708000
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	34000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	47000
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	146000
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	252000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	110000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	154000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	558000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	273000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18665000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21630000
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2017	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.75
CY2017	us-gaap	Depreciation Depreciation	78000
CY2016	us-gaap	Depreciation Depreciation	39000
CY2015	us-gaap	Depreciation Depreciation	47000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	78000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	39000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.23
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.29
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4900000
CY2015	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-23000
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2016	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2015	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2017Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2016Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2015Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2965000
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2761000
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2687000
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	8172000
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4185000
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3505000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2277000
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	344000
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	136000
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	89000
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	7000
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	94000
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	5000
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1238000
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-315000
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-335000
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	135000
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	89000
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	51000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	377000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-17000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	228000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-33000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-65000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	415000
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	530000
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-416000
CY2017	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	25000
CY2016	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	26000
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	96000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	32000
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-27000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	82000
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	11000
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-16000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	110000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	129000
CY2016	us-gaap	Interest Expense InterestExpense	1736000
CY2015	us-gaap	Interest Expense InterestExpense	1386000
CY2017	us-gaap	Interest Expense InterestExpense	0
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	29000
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	76000
CY2017Q4	us-gaap	Inventory Net InventoryNet	191000
CY2016Q4	us-gaap	Inventory Net InventoryNet	135000
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	70000
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	59000
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	92000
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves
CY2017	us-gaap	Inventory Write Down InventoryWriteDown
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	597000
CY2015	us-gaap	Inventory Write Down InventoryWriteDown
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	144000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4396000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7521000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-136000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18921000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-125000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8671000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5522000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7023000
CY2016Q4	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P5Y
CY2017Q4	us-gaap	Liabilities Liabilities	2413000
CY2016Q4	us-gaap	Liabilities Liabilities	1500000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13538000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22082000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2332000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1444000
CY2017	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Contingencies</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> aware of any current legal or administrative proceedings that are likely to have a material effect on the Company’s business, financial position, results of operations, or cash flows.</div></div></div>
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-12308000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-10310000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-6697000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	97000
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2702000
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1288000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-12405000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-7608000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-5409000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2485000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	594000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	649000
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	630000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	612000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	601000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	321000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	266000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000
CY2017	us-gaap	Other Operating Income OtherOperatingIncome	95000
CY2016	us-gaap	Other Operating Income OtherOperatingIncome
CY2015	us-gaap	Other Operating Income OtherOperatingIncome
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	1736000
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	1387000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	136000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	125000
CY2017	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1800000
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	340000
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	356000
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	1800000
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2015	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	144000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	22000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	59000
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	27000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	927000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	882000
CY2017	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 36pt;"></td> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(j)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Long-Lived Assets</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: 0pt;">The Company evaluates long-lived assets such as property and equipment whenever events or changes in circumstances indicate the carrying amount of an asset <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount. When undiscounted future cash flows are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to be sufficient to recover an asset<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">’s carrying amount, the asset is written down to its fair value. There have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> </div></div>impairments of the Company’s long-lived assets in any of the years presented. </div></div></div></div>
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	169000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	111000
CY2016	us-gaap	Revenues Revenues	576000
CY2015	us-gaap	Revenues Revenues	904000
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	389000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5799000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3330000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1518000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72450000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60142000
CY2017	us-gaap	Revenues Revenues	479000
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	517000
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	860000
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6395000
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4108000
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3734000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	2707000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	942000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	283000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1556234
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.28
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	144000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	137000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	33948
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	842653
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.80
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.33
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	39046000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1890000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3491937
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4213100
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.78
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.96
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.87
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.48
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.66
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	844000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y328D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y255D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y36D
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	12156000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	59000
CY2017Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	0
CY2016Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	0
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	87542
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7781000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	22000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	144000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-43117000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-3442000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	20582000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11125000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	608000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	531000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	725000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	117000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	77000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	511000
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	398000
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 36pt;"></td> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(c)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: 0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property and equipment; allowances for doubtful accounts and sales returns; inventory valuation; fair value of the convertible preferred stock warrant liability; fair value of the maturity date preferred stock warrant liability; fair value of the convertible shareholder notes derivative liabilit<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">y; and share-based compensation.</div></div></div></div>
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-3000000
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2800000
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38160543
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8368284
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1560293

Files In Submission

Name	View Source	Status
0001437749-18-004870-index-headers.html	Edgar Link	pending
0001437749-18-004870-index.html	Edgar Link	pending
0001437749-18-004870.txt	Edgar Link	pending
0001437749-18-004870-xbrl.zip	Edgar Link	pending
bcda-20171231.xml	Edgar Link	completed
bcda-20171231.xsd	Edgar Link	pending
bcda-20171231_cal.xml	Edgar Link	unprocessable
bcda-20171231_def.xml	Edgar Link	unprocessable
bcda-20171231_lab.xml	Edgar Link	unprocessable
bcda-20171231_pre.xml	Edgar Link	unprocessable
bcda20171231_10k.htm	Edgar Link	pending
ex_107468.htm	Edgar Link	pending
ex_107469.htm	Edgar Link	pending
ex_107470.htm	Edgar Link	pending
ex_107471.htm	Edgar Link	pending
ex_107472.htm	Edgar Link	pending
ex_107519.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
graph1.jpg	Edgar Link	pending
graph2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCDA
BioCardia, Inc. Stock $bcda

2017 Form 10-K Financial Statement

#000143774918004870 Filed on March 16, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCDA BioCardia, Inc. Stock $bcda

2017 Form 10-K Financial Statement

#000143774918004870 Filed on March 16, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCDA
BioCardia, Inc. Stock $bcda